Analyst consensus rating
Tarsus Pharmaceuticals Analyst Rating: Strong Buy
Direct answer
Tarsus Pharmaceuticals's consensus rating is Strong Buy.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $98.89.
Forecast evidence checked November 3, 2026.
Get free Tarsus Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $73.32
- Average price target
- $98.89
- High price target
- $116.00
- Low price target
- $84.00
- Low target gap
- +14.6%
- Target upside
- +34.9%
- High target gap
- +58.2%
- Target range width
- 43.6%
- Consensus rating
- Strong Buy
- Analysts
- 9
- Evidence date
- November 3, 2026
- Valid through
- November 10, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals has a verified Strong Buy consensus. The same dataset has an average price target of $98.89.
How far are Tarsus Pharmaceuticals's low and high targets from the recorded price?
The low target implies +14.6%, while the high target implies +58.2%.
How many analysts are included in Tarsus Pharmaceuticals's consensus?
The verified consensus includes 9 analysts.
How is Tarsus Pharmaceuticals's target upside or downside calculated?
The average target of $98.89 is divided by the recorded price of $73.32, then one is subtracted to produce +34.9%. This does not guarantee a future return.
When was Tarsus Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-11-03. The dataset is valid through 2026-11-10.